Cambrium designs, scales and manufactures novel molecular building blocks, including its NovaColl™ collagen alternative, for personal care, fashion and beyond. The company’s platform leverages AI, automation and synthetic biology to develop innovative biomolecules. Cambrium intends to scale manufacturing and commercial activities to fully replace traditional animal‑derived collagen. Management plans to use its new funding to translate early NovaColl™ successes into lasting impact and to accelerate its product pipeline. It expects to launch molecules for new applications and industries within the next two years. Cambrium is led by CEO Mitchell Duffy and has raised €11M to date, including prior funding from Merantix.

Total raised

$8M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2023